SFG
FOLD

SevenBridge Financial Group’s Amicus Therapeutics FOLD Stock Holding History

SevenBridge Financial Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-300
Closed -$4K – 297
2019
Q2 		$4K Hold
300
– – ﹤0.01% 538
2019
Q1 		$4K Hold
300
– – ﹤0.01% 508
2018
Q4 		$3K Hold
300
– – ﹤0.01% 490
2018
Q3 		$4K Hold
300
– – ﹤0.01% 502
2018
Q2 		$5K Hold
300
– – ﹤0.01% 492
2018
Q1 		$5K Buy
+300
New +$4.57K ﹤0.01% 502

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SevenBridge Financial Group's FOLD Position: Q3 2019 in Review

SevenBridge Financial Group sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 300 shares — an estimated $4K sold.

SevenBridge Financial Group first reported a position in FOLD in Q1 2018 and held it in 6 quarters. The position peaked at $5K in Q2 2018. 205 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • SevenBridge Financial Group reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • SevenBridge Financial Group sold 300 Amicus Therapeutics shares in Q3 2019, an estimated $4K.
  • SevenBridge Financial Group first reported a position in Amicus Therapeutics in Q1 2018 and held it in 6 quarters.
  • SevenBridge Financial Group's Amicus Therapeutics position peaked at $5K in Q2 2018.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on SevenBridge Financial Group's 13F filing for Q3 2019, filed 9 Oct 2019.